About My Health Careers Internship MedBlogs Contact us

Drug Induces Morphologic, Molecular Remissions in Myelofibrosis Patients

by Bidita Debnath on December 12, 2013 at 11:06 PM
Font : A-A+

 Drug Induces Morphologic, Molecular Remissions in Myelofibrosis Patients

A Mayo Clinic study has found that Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis.

The results were presented at the 2013 American Society of Hematology Annual Meeting in New Orleans.


"These are early results but they are promising, says the study's lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. "Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease."

Myelofibrosis is a chronic myeloid cancer in which bone marrow cells that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their blood stem cells, including JAK2, MPL, CALR, ASXL1 and spliceosome pathway mutations.

"Typically, myelofibrosis is characterized by marrow scarring and although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow," Dr. Tefferi says. "Some patients in our trial have reverted back to normal bone marrow."

Imetelstat works by inhibiting telomerase activity in tumor cells which leads to cell death.

Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for a minimum of six months. Among the 22, five patients achieved complete or partial remissions, including reversal of bone marrow fibrosis in four of the five patients. Two of the five patients with complete or partial remission have also experienced complete molecular remissions. The overall response rate was 41 percent.

Co-authors include Kebede Begna, M.D., Rebecca Laborde, Ph.D., Mrinal Patnaik, M.B.B.S., Curtis Hanson, M.D., Animesh Pardanani, M.B.B.S., Ph.D., Terra Lasho, Darci Zblewski, Christy Finke, Lauren Schimek, and Betsy LaPlant, all of Mayo Clinic and Monic Stuart, M.D., M.P.H. of Geron Corporation.

Financial support for the study was provided by Geron Corporation.

About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.

Source: Newswise

News A-Z
News Category
What's New on Medindia
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
How to Battle Boredom during COVID
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity 

Recommended Reading
Mayo Clinic Research Suggests Drug Induces Clinical Remissions in Myelofibrosis
A Mayo Clinic study has found that imetelstat, a novel telomerase inhibiting drug, has been found .....
New Drug Extends Survival Rate in People With Myelofibrosis
Ruxolitinib improves survival and quality of life in patients with a life-threatening bone cancer .....
Myelofibrosis Symptoms may be Reduced in a Better Manner by Ruxolinitib
A multicenter study has found that ruxolinitib is better than off-label chemotherapy drugs reducing ...
Rapid, Durable Relief for Myelofibrosis Patients Provided by JAK Inhibitor
Study says an oral medication produces significant and lasting relief for patients with ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use